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Objective: To validate the adapted Italian version of the Non-Motor Symptoms Scale (NMSS), a tool to
assess non-motor symptoms (NMS) in Parkinson's disease (PD).
Methods: A cross cultural adaptation of the NMSS into Italian and a psychometric analysis of the
translated version of the NMSS was carried out in patients with PD from two university centres
eafﬁliated hospitals. The quality of data and the acceptability, reliability and construct validity of NMSS
were analyzed. The following standard scales were also applied: Hoehn and Yahr staging, Uniﬁed Par-
kinson's Disease Rating Scale (UPDRS) part III, Montreal Cognitive Assessment, Beck Depression In-
ventory, Neuropsychiatric Inventory, Epworth Sleepiness Scale, Autonomic Scale for Outcomes in
Parkinson's disease-Motor, Movement Disorder Society-Sponsored Revision of the Uniﬁed Parkinson's
Disease Rating Scale part I and Modiﬁed Cumulative Illness Rating Scale (CIRS). Levodopa equivalent
daily dose (LEDD) was calculated.
Results: Seventy-one patients with PD were assessed (mean age years 69.8 ± 9.6 SD; 31% women; mean
length of disease 6.3 ± 4.6 years; H&Y median: 2). Mean NMSS was 39.76 (SD 31.9; skewness 0.95). The
total score of NMSS was free of ﬂoor or ceiling effects and showed a satisfactory reliability (Cronbach's
alpha coefﬁcient on total score was 0.72 [range for domains: 0.64e0.73], SEM value was 3.88 [½
SD ¼ 31.90]). Signiﬁcant positive correlations were found among total NMSS and other NMS standard
tests, but no signiﬁcant correlation appeared with UPDRS part III, CIRS and LEDD.
Conclusions: The Italian NMSS is a comprehensive and helpful measure for NMS in native Italian patients
with PD.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Parkinson's disease (PD) is a progressive neurological condition,
characterized by a dopamine deﬁciency causing tremor, rigidity,
bradykinesia and gait problems mainly arising from dopamine
deﬁciency. During the last decade, PD has been increasinglylogy, Department of Clinical
iversity Hospital, Milan, Italy.
Ltd. This is an open access article urecognized as also implying non-dopaminergic dysfunction and
non-motor symptoms (NMS) that can appear at all stages of the
disease [1] and have a relevant impact on patients' health and
quality of life [2e5].
Non-motor symptoms mainly include neuropsychiatric symp-
toms, sleep disorders, autonomic dysfunction, gastrointestinal
symptoms and sensory symptoms [6]. Unfortunately, NMS are still
underdiagnosed, and therefore undertreated [7]. A comprehensive
assessment including both motor and non-motor symptoms is
essential in clinical practice [8], but adequate instruments for the
detection and assessment of the burden of NMS in patients with PD
are still lacking in Italy.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and validated for a comprehensive assessment of non-motor
symptoms [9]. The NMSS is a 30-item scale including the
following 9 domains: cardiovascular, sleep/fatigue, mood/cogni-
tion, perceptual problems, attention/memory, gastrointestinal,
urinary, sexual function and miscellaneous.
Although translations in several languages exist, the NMSS has
not yet been translated into Italian.
The aim of this study was to perform a translation and adap-
tation of the NMSS into Italian following a precise translation
protocol based on international standards, and to analyze the
reliability and construct validity of the translated version and its
usefulness as a measure for non-motor symptoms in Italian pa-
tients with PD.
2. Methods
2.1. Study participants
We enrolled consecutive outpatients with PD from two uni-
versity centres-afﬁliated hospitals in Italy - in Rome and Milan-
between September 2015 and December 2015. PD was deﬁned
according to Gelb's criteria [10]. The NMSS was based on structured
questions that movement specialists already use in several coun-
tries, and the assessment is an example of good clinical practice.
Thus, speciﬁc approval for use of the scale was not required.
However, we have speciﬁed in the informed consent form and the
informative sheet submitted to all patients included in this study
that it is essential to investigate the possible presence of non-motor
symptoms and that this study could provide additional insights into
Parkinson's disease. Moreover, the study protocol was proposed in
accordance with the standards of good clinical practice and the
current revision of the Declaration of Helsinki. Personal data were
treated in accordance with Italian privacy laws. The written
informed consent to participate was obtained from all patients.
2.2. Adaptation of the NMSS
The NMSS was adapted into Italian from the original English
version following a precise translation protocol based on interna-
tional standards [11,12]. First, the NMSS was translated into Italian
by two professional translators, and then a reconciled version was
elaborated by an independent translator competent in movement
disorders and highly proﬁcient in both languages (NV), who iden-
tiﬁed and resolved any possible inadequate expressions or dis-
crepancies between the two forward translations. Then, a
professional translator, different from the translators who per-
formed the original English-to-Italian translation and with no
knowledge of the English original scale, translated the reconciled
version back into English. This back-translation was compared to
the original version by a panel of experts to verify the equivalence
of the two English versions in terms of meaning and conceptual
content. The two versions resulted equivalent, thus the last Italian
version of the NMSS was considered ﬁnal. The translated instru-
ment was then pre-tested on 10 patients with PD to assess their
understanding of the questions. Nomajor issues were found during
the pre-testing phase, thus the ﬁnal joint translation was carried
out, named NMSS-PD Italian version (esupp. ﬁle 1).
2.3. Patients assessment
Demographic data including age, gender and education, and
information on the disease such as age at onset, length of disease
and treatment were collected. The levodopa equivalent daily dose
(LEDD) [13] was calculated.All patients underwent a clinical examination. The Hoehn and
Yahr scale (H&Y) [14] and the Uniﬁed Parkinson's Disease Rating
Scale (UPDRS) part III [15] were used for the motor assessment and
the staging of disease. Somatic comorbidities were quantiﬁed using
the Modiﬁed Cumulative Illness Rating Scale (CIRS) [16].
The answers to the NMSS were obtained through interviews
carried out by the neurologist in regular follow-up visits. The
NMSS-PD scale includes 30 items grouped in the following 9 do-
mains: cardiovascular (2 items); sleep/fatigue (4 items); mood/
apathy (6 items); perceptual problems/hallucinations (3 items);
attention/memory (3 items); gastrointestinal tract (3 items); uri-
nary function (3 items); sexual function (2 items); and miscella-
neous (4 items). The assessment period was “the past 1 month”.
The scores for each item are based on a combination of severity
(from 0 to 3) and frequency scores (from 1 to 4), to capture
symptoms that are severe but relatively infrequent or that are less
severe but persistent. The total NMSS score ranges from 0 to 360.
Non-motor symptoms were further investigated, in addition to
the NMSS, by specialized clinical psychologists (CP or GA) in the
centre of Rome using a set of tests including theMontreal Cognitive
Assessment (MoCA) [17] to assess cognitive disorders, the Beck
Depression Inventory (BDI) [18] for depression, the Neuropsychi-
atric Inventory (NPI) [19] for behavioral disturbances, the Epworth
Sleepiness Scale (ESS) [20] for sleepiness, the Autonomic Scale for
Outcomes in Parkinson's disease-Motor (SCOPA-Aut) [21] for
autonomic issues, and the Movement Disorder Society-Sponsored
Revision of the Uniﬁed Parkinson's Disease Rating Scale (MDS-
UPDRS) part I [22] for a global non-motor assessment.
For most rating scales (BDI, NPI, ESS, SCOPA-AUT and MDS-
UPDRS part I), higher scores reﬂect higher severity on the
construct being measured, whereas for MoCA lower scores corre-
spond to worse cognitive performances.
To evaluate the stability of the Italian version of the NMSS (test-
retest reliability), a group of patients (n 15) repeated the NMSS two
weeks after the ﬁrst evaluationwith a different researcher than the
one who performed the previous evaluation (CP or GA).
2.4. Data analysis
Descriptive statistics were used for the characterization of the
sample. The univariate ANOVA test for continuous variables and the
Pearson's c2 test for categorical variables were used to compare
separately the characteristics of males and females among the two
groups of patients (Rome and Milan).
The following characteristics were explored for the Italian
version of the NMSS.
2.4.1. Quality of data
The proportion of computable data was considered adequate if
more than 95% of the NMSS data were fully computable [9].
2.4.2. Acceptability
The range of scores, the ﬂoor and ceiling effects (maximum
acceptable value for both: 15%), and the skewness (limits: 1
and þ1) were calculated.
2.4.3. Reliability
Precision for the NMSS domains was determined by means of
the standard error of measurement (SEM), the smaller the standard
error of measurement, the more reliable the test (a SEM value < ½
standard deviation was used as a criterion of acceptable precision).
Internal consistency was tested using the Cronbach's alpha co-
efﬁcient (values  0.70 was considered appropriate). Test-retest
reliability over a time interval of 14 days was assessed in a group
of 15 patients through the Intra-class Correlation (ICC), for which
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2.4.4. Construct validity
For convergent and divergent validity, we explored the rela-
tionship among the different domains of NMSS with other mea-
sures for the same construct (or other related constructs) and
motor scores, respectively, by means of Pearson's correlation co-
efﬁcient (r). A r value of at least 0.30 has been used as evidence for
convergent validity and less than 0.30 indicated evidence for
divergent validity.
Standard values for acceptability and reliability were estab-
lished based on previous studies [9,23,24]. Statistical analyses were
performed by means of the Statistical Package for the Social Sci-
ences (SPSS 23).
3. Results
Seventy-one patients (43 patients in Rome and 28 in Milan)
(mean age 69.8 ± 9.6 SD; 31% women; 48% non-tremor subtype of
PD) were included in the study. Included patients had amean age at
the onset of symptoms of 63.3± 9.6 years (range: 40e82 years), and
a mean length of the disease of 6.3 ± 4.6 years. The median H&Y
stage was 2 (stage 1, 18.3%; stage 2, 52.1%; stage 3, 26.7%; stage 4,
1.4%) and the median LEDD was 506.6 ± 319.0.
Demographic variables and clinical features (length of the dis-
ease in years, subtype of disease, motor assessment, comorbidities,
LEDD, NMSS total score) did not differ between patients from Rome
and patients from Milan.
Score distribution of NMSS and other scales are shown in
Table 1.
Complete data on the NMSS were available for 97.2% of the
enrolled patients (the only missing information was sexual func-
tioning for two patients).
The acceptability of the NMSS and the distribution of scores for
each domain are shown in Table 2.
As for the NMSS domains, only one domain (urinary function)
covered the full possible range of scores (Table 2). All domains
showed a ﬂoor effect. The most prominent ﬂoor effects were
observed in the following domains: perceptual problems/halluci-
nations (76%), sexual function (69.6%), cardiovascular function
(59.2%). No ceiling effect was observed on the NMSS domains.
Neither a ﬂoor nor a ceiling effect was observed in the NMSS total
score (Table 2). The NMSS skewness was 0.95, indicating that the
distribution is moderately right-skewed (its right tail is longer and
most of the distribution is centered on the left) [25].Table 1
Assessment of motor symptoms, non-motor symptoms, and comorbidities in
patients with Parkinson's disease.
N Mean SD Min Max
UPDRS III 46 16.2 8.0 6 40
MOCA 43 23.3 4.5 11 29
BDI 43 8.8 6.9 0 30
NPI 43 8.0 7.0 0 28
ESS 43 5.1 4.1 0 20
SCOPA aut 43 13.2 7.5 0 30
MDS-UPDRS I 43 9.7 5.3 0 22
NMSS 71 39.8 31.9 0 154
CIRS 71 0.5 0.2 0 1.2
SD, standard deviation; Min, minimum; Max, maximum.
UPDRS III, Uniﬁed Parkinson's Disease Rating Scale part III; MOCA, Montreal
Cognitive Assessment; BDI, Beck Depression Inventory; NPI, Neuropsychiatric In-
ventory; ESS, Epworth Sleepiness Scale, SCOPA-Aut, Autonomic Scale for Outcomes
in Parkinson's disease-Motor; MDS-UPDRS part I, Movement Disorder Society-
Sponsored Revision of the Uniﬁed Parkinson's Disease Rating Scale part I; NMSS,
Non Motor Symptoms Scale; CIRS, Modiﬁed Cumulative Illness Rating Scale.The SEMs values for the NMSS domains were small, ranging
from 0.23 (perceptual problems/hallucinations;½ SD¼ 0,93) to 1.13
(mood/apathy; ½ SD ¼ 4,65). SEM value for total score was 3.88
(value lower of ½ SD of total score).
Internal consistency was adequate, as the Cronbach's alpha co-
efﬁcient resulted 0.72 for the total scale. The Cronbach's alpha co-
efﬁcients for the 9 NMSS subscales were respectively 0.72, 0.64,
0.68, 0.73, 0.69, 0.69, 0.68, 0.73 and 0.71.
Test-retest reliability of the total NMSS score was assessed in a
subset of patients with PD (n ¼ 15), and a high correlation coefﬁ-
cient (ICC 0.83, p < 0.0001) was reported.
The NMSS total score did not result signiﬁcantly correlated with
the age of patients. A weak association was observed between
NMSS total score and disease duration (r 0.23, p < 0.05). No sig-
niﬁcant correlation was observed between LEDD and NMSS total
score (r 0.20, p ¼ 0.09).
Highly signiﬁcant correlations were observed between the total
score of the NMSS-PD and all the other scales used to assess non-
motor symptoms, but not with the scales used for motor symp-
toms, such as the UPDRS III (Table 3). No signiﬁcant correlationwas
observed between the NMSS and comorbidities assessed with CIRS.
The observed correlations between each of the domains included in
the NMSS and the other considered scales are shown in Table 3.
A signiﬁcant correlation was observed between all of the sub-
scale domains included in the NMSS, with the exception of sexual
domain, and the total score (Table 4), indicating a strong association
with the related construct.
4. Discussion
The Italian version of the NMSS resulted a comprehensive in-
strument to assess NMS burden in Italian patients with PD, and
showed adequate satisfactory clinimetrics in terms of data quality,
precision, acceptability, internal consistency and reliability. This
scale is easy and short to complete, and showed a signiﬁcant cor-
relation with other NMS assessments, such as BDI, MoCA, NPI,
SCOPA-Aut, ESS, MDS-UPDRS part I. As for the BDI, NPI, SCOPA-Aut,
and ESS, a signiﬁcant correlation (p < 0.05) was also found with
NMSS domains. Interestingly, no correlation was found between
the NMSS and comorbidities assessed with the CIRS. This
strengthens the idea that non-motor symptoms are an integrating
part of PD rather than being part of different diseases.
To our knowledge, no other previous study assessed the metric
properties of the Italian version of the NMSS. Previous independent
validations of this scale are available for Chinese, Korean, Brazilian
and Arabic languages. The validation and widespread availability of
a simple and complete NMS assessment could allow the systematic
collection of data on non-motor features of patients with PD across
different countries. Comparing these epidemiological data may also
help to outline different non-motor PD subtypes [26].
As in the original validation study, the Italian NMSS total score
was free of both a ﬂoor and a ceiling effect. Similarly, none of the
domains showed a ceiling effect, while a ﬂoor effect was found in all
domains.
No signiﬁcant associationwas observed between the total scores
from the Italian NMSS and the UPDRS part III. This result differed
from the ﬁndings from the original study [9].
This data support the view that the burden of non-motor
symptoms is independent from the severity of motor signs, at
least in the earliest stages of the disease: the patients enrolled in
our study were in a less severe motor stage of PD compared to the
patients enrolled in the original study (H&Y  2, 71.4% vs. 55.5%).
The mean total NMSS score in our study was 39.7 ± 31.9, which
is lower than the mean score observed in the original Chaudhuri's
validation [9] and Arabic version [24], and higher than the mean
Table 2
Acceptability of the Non-Motor Symptoms Scale (NMSS) in Parkinson's disease.
NMSS Mean SEM SD Min Max Floor effect, % Ceiling effect, %
Cardiovascular 1.35 0.27 2.25 0 8 59.2 4.2
Sleep/Fatigue 7.65 0.94 7.73 0 36 22.5 1.4
Mood/Apathy 5.86 1.13 9.31 0 49 35.2 1.4
Perceptual problems 0.90 0.23 1.86 0 7 76.1 2.8
Attention/Memory 3.39 0.68 5.62 0 27 45.1 2.8
Gastrointestinal 6.04 0.78 6.41 0 23 31,0 1.4
Urinary 7.87 1.06 8.70 0 36 25.4 2.8
Sexual function 1.94 0.43 3.56 0 14 67.6 1.4
Miscellaneous 4.80 0.78 6.47 0 26 39.4 1.4
Total score 39.76 3.88 31.90 0 154 7.0 1.4
SEM, standard error of measurement; SD, standard deviation; Min, minimum; Max, maximum.
Table 3
Correlations between each of the domains included in the Non-Motor Symptoms Scale (NMSS) and the other considered scales, analyzed with the Pearson's correlation
coefﬁcient.
NMSS UPDRS III MOCA BDI NPI ESS SCOPA-Aut MDS-UPDRS I CIRS
Cardiovascular 0.19 0.21 0.29 0.21 0.41** 0.25 0.46** 0.05
Sleep/Fatigue 0.13 0.11 0.57** 0.55** 0.37* 0.35* 0.75** 0.19
Mood/Apathy 0.01 0.01 0.58** 0.66** 0.20 0.21 0.40** 0.20
Perceptual problems 0.07 0.03 0.28 0.40** 0.06 0.05 0.22 0.12
Attention/Memory 0.06 0.21 0.50** 0.27 0.20 0.05 0.40* 0.06
Gastrointestinal 0.28 0.15 0.32* 0.28 0.33* 0.56** 0.45** 0.01
Urinary 0.33* 0.37* 0.04 0.34 0.27 0.72** 0.63** 0.19
Sexual function 0.13 0.14 0.07 0.05 0.02 0.50** 0.09 0.20
Miscellaneous 0.09 0.02 0.22 0.29 0.23 0.17 0.41** 0.26
Total score 0.28 0.27 0.56** 0.65** 0.45** 0.66** 0.85** 0.23
*p < 0,05 **p < 0,001.
UPDRS III, Uniﬁed Parkinson's Disease Rating Scale part III; MOCA, Montreal Cognitive Assessment; BDI, Beck Depression Inventory; NPI, Neuropsychiatric Inventory; ESS,
Epworth Sleepiness Scale, SCOPA-Aut, Autonomic Scale for Outcomes in Parkinson's disease-Motor; MDS-UPDRS part I, Movement Disorder Society-Sponsored Revision of the
Uniﬁed Parkinson's Disease Rating Scale part I; NMSS, Non Motor Symptoms Scale; CIRS, Modiﬁed Cumulative Illness Rating Scale.
Table 4
The domainsetotal Non-Motor Symptoms Scale (NMSS)
score correlation.
NMSS r
Cardiovascular 0.35**
Sleep/Fatigue 0.80**
Mood/Apathy 0.71**
Perceptual problems 0.32**
Attention/Memory 0.57**
Gastrointestinal 0.62**
Urinary 0.70**
Sexual function 0.26
Miscellaneous 0.54**
*p < 0,05 **p < 0,001.
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sions of the NMSS. These differences may reﬂect differences in age,
ethnicity, duration of disease and motor stages in the recruited
populations. Furthermore, in our study, we did not ﬁnd a signiﬁcant
correlation between the NMSS total score and the LEDD. This
ﬁnding is similar towhat is reported by the validations of the Arabic
and Chinese versions [23,24], and suggests that the side-effects of
the dopaminergic treatment may not be the main causes of NMS.
The present study may have the following limitations: 1) lack of
comparable measures for all assessed NMS; 2) small sample-size, in
particular of the patients enrolled to study test-retest reliability; 3)
relatively low number of patients with PD reaching both the ex-
tremes of the severity classiﬁcation; patients in the advanced
stages of the disease may have been underrepresented.
Therefore, a large scale study including more patients with PD
may help to provide a more complete proﬁle of NMS in Italian
patients with PD.In conclusion, our study showed that the Italian version of the
NMSS is a helpful instrument for the assessment of the burden of
non-motor symptoms in Italian patients with PD.
NMSS is a very quick and easy scale to administer and it should
be integrated into all PD outpatients clinics in Italy.
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